Syntermed Announces Expanded Availability of Emory Toolbox 4.0 and NeuroQ at RSNA

Share Article

Syntermed, Inc. announces that Emory Toolbox 4.0 and NeuroQ 3.6 will be available on the Philips Healthcare IntelliSpace Portal 7 platform. NeuroQ™ 3.6 brain imaging analysis assists in the differential diagnosis of dementias and tracks the progress of these diseases; Emory Toolbox 4.0, includes new levels of clinical decision support for cardiac imaging.

Dementia PET-FDG brain scans

Syntermed's NeuroQ™ 3.6 brain imaging analysis assists in the differential diagnosis of dementias and tracks the progress of these diseases.

NeuroQ 3.6 is a significant upgrade from version 3.0 with many clinical and workflow enhancements, plus support for Amyloid studies and same patient serial studies which provides analysis for the progression of disease. -- Michael Lee, Syntermed, Inc.

At this week's RSNA 2014 meeting in Chicago, Syntermed, Inc. announced that Emory Toolbox (ECTb) 4.0 and NeuroQ 3.6 will be available on the Philips Healthcare IntelliSpace Portal 7 platform. Presently, Philips Healthcare offers Syntermed's NeuroQ 3.6 software for PET-FDG and Amyloid brain imaging quantitative analysis on Philips IntelliSpace Portal 6. Starting in 2015, Syntermed's NeuroQ v3.6 will also be available on the Philips IntelliSpace Portal 7 platform.

Syntermed, Inc. and Philips Healthcare are both exhibitors at the 100th anniversary of the RSNA annual meeting. A full snapshot of both the Syntermed Emory Toolbox and NeuroQ product lines can be seen at the RSNA exhibitor digital profile.

"Emory Toolbox 4.0 includes Syntermed IDS™ which is the first FDA approved clinical decision support for nuclear cardiology designed to maintain the highest quality interpretations and expedite workflow. As risk based payment models mature, every medical procedure, including diagnostic imaging, is under greater scrutiny and providers must be able to effectively demonstrate the value of procedures,” says Michael Lee, CEO, Syntermed. "NeuroQ 3.6 is a significant upgrade from version 3.0 offering many clinical and workflow enhancements plus support for Amyloid studies, as well as, same patient serial studies which provides analysis for the progression of disease.”

Syntermed's website now offers updated software references and content for its nuclear cardiology and brain imaging product lines and includes several new staff training and demonstration resources. Syntermed’s EmoryToolbox 4.0 with SmartReport, powered by Syntermed IDS was FDA cleared in May2013. EmoryToolbox™4.0 is the result of an award (1R42HL106818-01) from the National Heart, Lung and Blood Institute titled, “Novel WEB Decision Support System for cardiac image interpretation and reporting” funded through the Small Business Technology Transfer (STTR) program of NHLBI.

About Syntermed, Inc.: An Atlanta-based imaging and informatics company supporting SPECT and PET imaging for heart and brain studies with quantification, reporting and decision support software.

Syntermed signature products:Syntermed's NeuroQ 3.6 brain imaging software and Amyloid brain imaging, and now NeuroQ SPECT brain imaging software, is used in the differential diagnosis of dementia. Emory Toolbox, now in its fourth generation, is utilized by nuclear cardiology labs worldwide; SyncTool™ is for advanced phase analysis imaging studies of left ventricle dyssynchrony.

Michael Lee, CEO, and Ken Van Train, President will be available at the RSNA meeting, Syntermed Booth 7711 (North Hall B) to provide additional details about Syntermed's pipeline products and market expansion.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Roberts
Visit website